SCHEMBL2479413

SCHEMBL2479413

NNc1ccc2c(c1)OCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.59
MAPT P10636 8/20 0.58
NPC1 O15118 7/20 0.58
RAB9A P51151 7/20 0.58
ALDH1A1 P00352 7/20 0.58
KMT2A Q03164 4/20 0.58
GAA P10253 3/20 0.58
MEN1 O00255 3/20 0.58
POLB P06746 2/20 0.58
NFKB1 P19838 2/20 0.53
NFKB2 Q00653 2/20 0.53
RELA Q04206 2/20 0.53
PKM P14618 1/20 0.51
HPGD P15428 3/20 0.50
HTT P42858 2/20 0.50
KDM4E B2RXH2 2/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
THRB P10828 1/20 0.49
ALOX12 P18054 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1881837 0.98 SMN1; SMN2 (0.58) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL13241 0.87 CYP1A2 (0.55) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
Hydrochloric Acid SCHEMBL20820057 0.85 CYP1A2 (0.53) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL378949 0.82 SMN1; SMN2 (0.62) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL1920755 0.80 NPC1 (0.60) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL1776108 0.78 MAPT (0.58) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL761129 0.78 MAPT (0.58) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL29528582 0.78 MAPT (0.58) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL12613199 0.78 SMN1; SMN2 (0.63) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL10089578 0.78 MAPT (0.58) SMN1; SMN2MAPTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055109-A1 IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS UNIV CALIFORNIA (US) 2026-02-26 US disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 US disclosed
CN-114835656-A 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof 天津中医药大学 2022-08-02 CN disclosed
US-9187455-B2 Substituted pyridazines as PDE10A inhibitors HOFFMANN-LA ROCHE INC. (US) 2015-11-17 US disclosed
EP-2398795-B1 HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-10-15 EP disclosed
EP-2373641-B1 PYRIDAZINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-12-19 EP disclosed
US-8178538-B2 Pyridazinones HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed
EP-2398795-A1 HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
EP-2373641-A1 PYRIDAZINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-10-12 EP disclosed
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP disclosed
EP-1246809-B1 5-ARYL-1H-1,2,4-TRIAZOLE COMPOUNDS AS INHIBITORS OF CYCLOOXYGENASE-2 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM THERAMEX (MC) 2003-07-16 EP disclosed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US disclosed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO disclosed
EP-1246809-A1 5-ARYL-1H-1,2,4-TRIAZOLE COMPOUNDS AS INHIBITORS OF CYCLOOXYGENASE-2 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LABORATOIRE THERAMEX (MC) 2002-10-09 EP disclosed
WO-2001034577-A1 5-ARYL-1H-1,2,4-TRIAZOLE COMPOUNDS AS INHIBITORS OF CYCLOOXYGENASE-2 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LABORATOIRE THERAMEX (MC) 2001-05-17 WO disclosed
EP-1099695-A1 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them LABORATOIRE THERAMEX S.A. (MC) 2001-05-16 EP disclosed
US-4293553-A ANTITHROMBOTIC AGENT Ishikawa, Masayuki (JP) 1981-10-06 US disclosed
US-4060550-A Novel n'-acylated phenyl-hydrazine and -hydrazone derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-11-29 US disclosed
US-3974145-A Novel N'-acylated phenyl-hydrazine and hydrozone derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 SMN1; SMN2 2799/4885MAPT 4855/4885NPC1 2371/4885
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 SMN1; SMN2 4286/4885MAPT 3251/4885NPC1 3782/4885
US-20260055109-A1 IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS HTR7, HTR3B, HTR3A SMN1; SMN2 982/4885MAPT 956/4885NPC1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.